SAB Biotherapeutics: Funding, Investors & Team (Sep 2026)
Targeted, totally human polyclonal antibodies for C diff, seasonal influenza, and Type 1 diabetes are being developed to advance a new class of immunotherapies without the use of human donors.
SAB Biotherapeutics has raised $223M across 3 funding rounds on record, the most recent an undisclosed round of $85.0M announced in Mar 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
SAB Biotherapeutics Company Profile and Key Stats
Latest funding round on record: Mar 2026.
SAB Biotherapeutics Funding Rounds
SAB Biotherapeutics raised $8.0M in an undisclosed round announced in Jan 2023.
9 months later, an undisclosed round of $130M was announced in Oct 2023.
2.4 years later, an undisclosed round of $85.0M was announced in Mar 2026.
SAB Biotherapeutics Founders and Leadership Team
Contact details for the SAB Biotherapeutics team: 1 of 2 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →SAB Biotherapeutics Funding Compared to Other Biotechnology Startups
SAB Biotherapeutics' latest round of $85.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like SAB Biotherapeutics in Biotechnology and Sioux Falls
Companies Similar to SAB Biotherapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
SAB Biotherapeutics Funding FAQs
What does SAB Biotherapeutics do?
Targeted, totally human polyclonal antibodies for C diff, seasonal influenza, and Type 1 diabetes are being developed to advance a new class of immunotherapies without the use of human donors.
How much funding has SAB Biotherapeutics raised?
SAB Biotherapeutics has raised $223M across 3 rounds on record. The most recent is an undisclosed round of $85.0M announced in Mar 2026.
When did SAB Biotherapeutics last raise funding?
SAB Biotherapeutics' most recent funding round on record is an undisclosed round of $85.0M, announced in Mar 2026.
Who founded SAB Biotherapeutics?
FundedIQ lists Eddie J Sullivan (Founder) at SAB Biotherapeutics.
Who is the CEO of SAB Biotherapeutics?
Eddie Sullivan is listed as CEO at SAB Biotherapeutics.
Where is SAB Biotherapeutics headquartered?
SAB Biotherapeutics is based in Sioux Falls, South Dakota, United States.
How many employees does SAB Biotherapeutics have?
SAB Biotherapeutics is in the 51-100 employee band.
How does SAB Biotherapeutics' funding compare to other Biotechnology startups?
SAB Biotherapeutics' latest round of $85.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's SAB Biotherapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for SAB Biotherapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.